Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Catalent acquires Cook Pharmica

by Ryan Cross
September 25, 2017 | A version of this story appeared in Volume 95, Issue 38

In a further consolidation of the contract drug-making industry, Catalent is purchasing Cook Pharmica and its 80,000-m2 facility in Bloomington, Ind., for $950 million. Catalent will pay $750 million cash when the deal closes, with the remainder delivered in four annual installments. The acquisition will bolster Catalent’s cell culture manufacturing and also biologics development, manufacturing, and packaging programs.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.